Association Between Common Cardiovascular Drugs and Depression

Depression and cardiovascular diseases (CVDs) share a bidirectional relationship, with each condition exacerbating the risk of the other. While CVDs such as coronary heart disease (CHD), hypertension, atrial fibrillation (AF), and heart failure (HF) are linked to a two- to threefold increased risk of depression, the role of cardiovascular medications in modulating this risk remains unclear. This review synthesizes evidence from clinical trials, observational studies, and mechanistic investigations to evaluate the association between seven major classes of cardiovascular drugs—statins, β-blockers, antiplatelet agents (e.g., aspirin), calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs), diuretics, and nitrates—and depression.

Pathophysiological Mechanisms Linking Cardiovascular Drugs to Depression

The interplay between cardiovascular drugs and depression involves shared pathways such as inflammation, oxidative stress, endothelial dysfunction, and neurotransmitter regulation. For instance, statins exert anti-inflammatory and antioxidant effects, potentially mitigating neuroinflammation implicated in depression. ACEIs/ARBs modulate the renin-angiotensin system (RAS), which influences stress responses and neuroinflammation. Conversely, CCBs alter calcium signaling in neurons, which may affect mood regulation, though the direction of this effect remains ambiguous. β-blockers, particularly lipophilic variants, penetrate the blood-brain barrier (BBB) and may interact with central adrenergic receptors, historically linked to depressive symptoms, though recent studies challenge this association.

Statins: Mixed Evidence with Promising Anti-Inflammatory Effects

Statins, primarily used for lipid-lowering, have been scrutinized for their psychiatric effects. Early case reports suggested statins might induce depression by reducing brain cholesterol synthesis, critical for neurotransmitter receptor function. However, large-scale studies refute this. A Swedish national cohort study (n=4,607,990) found statin use associated with an 8% reduction in depression risk. Similarly, a trial involving 465 stroke patients demonstrated that statins significantly reduced post-stroke depression (PSD) risk during follow-up (adjusted odds ratio [aOR] 0.63, 95% CI 0.43–0.93). Mechanistically, statins lower pro-inflammatory cytokines (e.g., IL-1β, NF-κB) and elevate brain-derived neurotrophic factor (BDNF) in animal models, supporting their neuroprotective role. However, randomized controlled trials (RCTs) like the YoDA-A trial (n=130) found no additional antidepressant benefit for rosuvastatin over placebo in major depressive disorder (MDD), highlighting dose- and context-dependent variability.

β-Blockers: Reassessing Historical Concerns

β-blockers, particularly propranolol, were historically associated with depression due to their lipophilicity and BBB penetration. A 2006 multicenter study (n=381 post-myocardial infarction patients) found no significant difference in depressive symptoms between β-blocker users and non-users over 12 months. Conversely, a 2017 prospective study on metoprolol in heart failure patients (n=154) reported increased Hospital Anxiety and Depression Scale (HADS) scores, suggesting drug-specific or population-specific effects. Notably, a 2020 Danish cohort study (n=3,747,190) found continued β-blocker use correlated with reduced depression rates (adjusted hazard ratio [aHR] 0.90, 95% CI 0.87–0.93), underscoring the need for subtype-specific analysis (e.g., lipophilic vs. hydrophilic agents).

Aspirin: Controversial Role in Inflammation and Mood

Aspirin’s anti-inflammatory properties have spurred interest in its potential antidepressant effects. A Swedish cohort study (n=316,904 cancer patients) linked aspirin use to a 12% lower risk of depression (HR 0.88, 95% CI 0.81–0.97). Preclinical studies in rodents show aspirin increases hippocampal serotonin and reduces cortisol, mimicking antidepressant effects. However, the ASPREE-D trial (n=19,114 older adults) found no preventive benefit for depression with low-dose aspirin over 4.7 years, possibly due to insufficient anti-inflammatory activity at lower doses. This discrepancy underscores the need for dose-response studies and consideration of comorbid conditions.

Calcium Channel Blockers: Dual Neurochemical Effects

CCBs like verapamil and nifedipine modulate neuronal calcium channels, affecting neurotransmitter release and synaptic plasticity. While animal studies suggest CCBs enhance imipramine’s antidepressant effects by increasing brain concentrations, human data are conflicting. A German case-control study (n=972 diabetics) linked CCB use to a twofold increased depression risk, whereas a U.S. RCT (n=218) found no association. The variability may stem from differences in BBB penetration, with lipophilic CCBs (e.g., verapamil) more likely to influence central pathways.

ACEIs/ARBs: Emerging Neuroprotective Candidates

ACEIs/ARBs target the RAS, which is implicated in both cardiovascular and neuropsychiatric regulation. A trial in 625 hypertensive men found ACEI use associated with reduced depression likelihood, possibly via anti-inflammatory effects on brain RAS. Captopril, an ACEI, improved quality of life and reduced depressive symptoms compared to methyldopa in a hypertension trial. However, robust RCTs are lacking, and current evidence remains preliminary.

Diuretics and Nitrates: Limited and Inconclusive Data

Diuretics are rarely linked to depression outside electrolyte imbalance cases. A Danish cohort study (n=3,747,190) found no association between diuretics and depression, while isolated case reports suggest transient mood effects. Nitrates, which modulate nitric oxide (NO) signaling, show mixed results: reduced plasma NO metabolites correlate with depression in some studies, but a case-control study (n=100) found no significant association.

Conclusions and Clinical Implications

Statins demonstrate the most consistent evidence for antidepressant effects, likely via anti-inflammatory and neuroprotective mechanisms. Aspirin and ACEIs/ARBs show potential but require further validation. β-blockers, once feared for depressive risks, now appear neutral in most populations. CCBs and diuretics present unclear risks, necessitating cautious monitoring. Clinicians should weigh these associations when prescribing, considering individual patient profiles and comorbidities. Future research must prioritize RCTs with standardized depression metrics and mechanistic studies to unravel drug-specific pathways.

doi.org/10.1097/CM9.0000000000001875

Was this helpful?

YesNo

1 / 0